Russian drugmakers aim to focus on design of original drugs

18 June 2024
russia_li

The Russian pharmaceutical market is undergoing a large-scale transformation, as the share of foreign drugs is steadily declining due to acceleration of processes of import substitution, reports The Pharma Letter’s local correspondent.

That leads to the ever-growing number of applications for pharmaceutical patents filed by Russian companies, which last year exceeded the number of applications from foreigners for the first time in the last seven years.

According to recent statements by Yuri Zubov, head of the Russian Patent Service (Rospatent), the current balance in the number of patent applications in the Russian pharmaceutical market is gradually shifting in favor of Russian drugmakers. However, according to him, while global drugmakers mainly patent new active ingredients – the so-called primary patents - most of Russian companies are focused on secondary patents, improving already known formulas and technologies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical